Antioxidant slows respiratory decline in Duchenne’s: Lancet

A drug initially developed to treat Alzheimer’s Disease may be a promising option for patients with Duchenne muscular dystrophy, a small phase III study in The Lancet suggests.  The placebo controlled study of 66 patients with Duchenne muscular dystrophy (DMD) who were not taking glucocorticoids showed significantly less decline in standard respiratory function measures including ...

Already a member?

Login to keep reading.

© 2022 the limbic